| Title: |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis ; Clin Infect Dis |
| Authors: |
GANTNER, P.; HESSAMFAR, Mojgan; SOUALA, M. F.; VALIN, N.; SIMON, A.; AJANA, F.; BOUVET, E.; ROUVEIX, E.; COTTE, L.; BANI-SADR, F.; HUSTACHE-MATHIEU, L.; LEBRETTE, M. G.; TRUCHETET, F.; GALEMPOIX, J. M.; PIROTH, L.; PELLISSIER, G.; MURET, P.; REY, D. |
| Publication Year: |
2020 |
| Subject Terms: |
MORPH3Eus; Sciences du Vivant [q-bio]/Santé publique et épidémiologie |
| Description: |
We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/cid/ciz577 |
| Availability: |
https://oskar-bordeaux.fr/handle/20.500.12278/25998; https://hdl.handle.net/20.500.12278/25998; https://doi.org/10.1093/cid/ciz577 |
| Rights: |
open |
| Accession Number: |
edsbas.84E55C3 |
| Database: |
BASE |